Work

Abstract PS5-08-19: Randomized phase 3 trial evaluating KAT6 inhibitor PF-07248144 plus fulvestrant in HR+HER2− advanced/metastatic breast cancer after progression on CDK4/6 inhibitor-based therapy

Year: 2026

Type: conference-abstract

Source: Clinical Cancer Research

DOI: 10.1158/1557-3265.sabcs25-ps5-08-19

Authors: K. M. Kalinsky, R. M. Layman, A. Giordano, T. Mukohara, Y. Park, G. J. Lindeman, G. Bianchini, A. Nonneville, V. Diéras, S. Kuemmel, S. Wang, Z. Shao, S. Kent, M. Li, M. Oliveira

Institutions: Emory University, The University of Texas MD Anderson Cancer Center, Dana-Farber Cancer Institute, National Cancer Centre Japan, National Cancer Center Hospital East, Samsung Medical Center, Sungkyunkwan University, Walter and Eliza Hall Institute of Medical Research, Peter MacCallum Cancer Centre, IRCCS Ospedale San Raffaele, Institut Paoli-Calmettes, Centre Eugène Marquis, Kliniken Essen-Mitte, Sun Yat-sen University Cancer Center, Fudan University Shanghai Cancer Center, Pfizer (United States), Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology

Language: English

Topic: Advanced Breast Cancer Therapies

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7129500610

Cites:

Cited by:

Related to: